- Published: June 2013
The Impact of iPads on pharma: a Primer
- Published: July 2011
- Region: World
- 33 Pages
With the launch of Apple's iPad in April 2010, the way we use technology changed forever. Instant, portable and quick, the iPad is expected to sell 50 million units in 2011 alone.
Its impact on Pharma is still being measured, but for an industry notoriously reluctant to adopt new technology, there is no doubt the iPad and tablets in general have changed the game. Already, major players such as Pfizer, AstraZeneca, Abbott, Novartis, Eli Lilly and sanofi-aventis have embraced the digital age, with more to come.
Yet many companies are still hesitating or are in the process of choosing technology, creating content and finding ways not only to integrate tablets, but use their functionality in innovative ways.
The Impact of iPads on Pharma: A Primer offers complete insight into how the iPad is being used and why. Logically broken down into a step-by-step approach, the report discusses all the major areas, from the business case for iPads and choosing a device to creating localized content and capturing iPad data in closed loop marketing to physicians. Containing interviews with some of the industry's leading experts, the report is an up-to-the-minute look at iPads, their growth potential and how the industry's relationship with digital technology is likely to evolve.
The business case for tablets in sales representative-physician interaction, increasing internal efficiency, minimizing costs and improving customer perception
Profile of major devices, including the debate over Android alternatives and cloud-based content
Examination of the four key points business must address in creating a tablet strategy
Discussion of the importance not only of content, but of using GPS to localize it
Maximizing the benefits of statistics gathered for closed-loop marketing
Importance of training in technology introduction strategies
Clear guidelines on what tablets mean for the industry and how to implement them
A step-by-step approach that touches on the major issues, benefits and potential problems
Expert input that presents a balanced and intelligent approach to tablet deployment
Key Questions Asked:
What has the industry learned since the introduction of iPad and tablet technology?
Who most benefits from tablet use and where is the growth occurring?
Which device is best and which has greater integration capability?
What is the best implementation and content delivery strategy?
How can tablet information be used in an iterative approach to closed loop marketing?
Who Should Read This Report:
Key account and territory managers
Communication and technology support teams SHOW LESS READ MORE >
- Making the business case for tablets
- Choosing a device
- Cementing a strategy
- Embracing content creation
- The value of data
- Introducing tablets
Making the business case for tablets
- Optimizing rep-physician interaction
- Increasing internal efficiency
- Minimizing cost
- Everyone else is doing it
Choosing a device
- The iPad appeal
- Android or agnostic?
Cementing a strategy
- Identifying the problem
- "Get in line"
- Internal competence and coordination
- Ensuring proper external partners
- Speed of deployment
Embracing content creation
- Taking advantage of touch
- Creating physician value
- Content is king
The value of data
- Closing the loop on closed loop marketing
- Overcoming software challenges
- Ensuring ROI
- 'Get to the basics'
- Teaching advanced functionality
- An iterative approach
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Site License||The report will be emailed to you. The report is sent in PDF format.||This is a site license, allowing all users within a given geographical location of your organisation access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|